Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T20:26:52.927Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic Malignant Syndrome in Striatonigral Degeneration

Published online by Cambridge University Press:  02 January 2018

W. R. G. Gibb
W. R. G. Gibb*
Affiliation:
Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale
*
∗National Hospitals for Nervous Diseases, Queen Square, London WC1N 3BG
Get access Rights & Permissions [Opens in a new window]

Abstract

A case of probable neuroleptic malignant syndrome (NMS) complicating l-dopa withdrawal in striatonigral degeneration is described. This case suggests that the hyperthermia of NMS is due to peripheral heat production associated with severe muscular rigidity secondary to withdrawal of striatal dopamine drive, rather than being centrally mediated by the hypothalamus, which is not involved in striatonigral degeneration.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 153 , Issue 2 , August 1988 , pp. 254 - 255
Copyright
Copyright © Royal College of Psychiatrists, 1988 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Figa-Talamanca, L., Gualandi, C., Di Meo, L., Di Battista, G., Neri, G. & Lo Russo, F. (1985) Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology, 35, 258–261.CrossRefGoogle ScholarPubMed
Gibb, W. R. G. & Griffith, D. N. W. (1986) Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgraduate Medical Journal, 62, 59–60.Google Scholar
Henderson, V. W. & Wooten, G. F. (1981) Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology, 31, 132–137.Google Scholar
Langston, J. W. & Forno, L. S. (1978) The hypothalamus in Parkinson's disease. Annals of Neurology, 3, 129–133.CrossRefGoogle Scholar
May, D. C., Morris, S. W., Stewart, R. M., Fenton, B. J. & Gaffney, F. A. (1983) Neuroleptic malignant syndrome: response to dantrolene sodium. Annals of Internal Medicine, 98, 183–184.Google Scholar
Oppenheimer, D. (1983) Neuropathology of progressive autonomic failure. In Autonomic Failure (ed. Bannister, R.). Oxford: Oxford University Press.Google Scholar
Sechi, G. P., Tanda, F. & Mutani, R. (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology, 34, 249–251.CrossRefGoogle ScholarPubMed
Toru, M., Matsuda, O., Makiguchi, K. & Sugano, K. (1981) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. Journal of Nervous and Mental Disease, 169, 324–327.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.